Twist Bioscience Corp TWST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TWST is a good fit for your portfolio.
News
-
Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor
-
Twist Bioscience Announces Participation in Department of Commerce Consortium Dedicated to AI Safety
-
Twist Bioscience to Present at Upcoming Investor Conferences
-
Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications
-
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results
-
Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024
Trading Information
- Previous Close Price
- $48.47
- Day Range
- $48.63–50.35
- 52-Week Range
- $14.42–55.26
- Bid/Ask
- $46.88 / $55.00
- Market Cap
- $2.85 Bil
- Volume/Avg
- 1 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.13
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.21%
Company Profile
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 919
- Website
- https://www.twistbioscience.com
Comparables
Valuation
|
Metric
|
TWST
|
PACB
|
TIHE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.08 | 0.56 | — |
Price/Sales | 10.13 | 1.74 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TWST
|
PACB
|
TIHE
|
|---|---|---|---|
Quick Ratio | 4.88 | 8.12 | — |
Current Ratio | 5.51 | 9.28 | — |
Interest Coverage | −103,596.50 | −20.82 | — |
Quick Ratio
TWST
PACB
TIHE
Profitability
|
Metric
|
TWST
|
PACB
|
TIHE
|
|---|---|---|---|
Return on Assets (Normalized) | −18.39% | −15.31% | — |
Return on Equity (Normalized) | −22.73% | −40.23% | — |
Return on Invested Capital (Normalized) | −21.58% | −16.22% | — |
Return on Assets
TWST
PACB
TIHE
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Jzbmpqfm | Cpgbz | $204.7 Bil | |||
| Danaher Corp
DHR
| Szkmpzcq | Xscwm | $178.2 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Ylkwbwssp | Fvvqvx | $39.9 Bil | |||
| IQVIA Holdings Inc
IQV
| Pqxtlkhg | Yyjdwf | $38.1 Bil | |||
| Agilent Technologies Inc
A
| Jmmjqcmtg | Zrk | $36.8 Bil | |||
| Mettler-Toledo International Inc
MTD
| Ffmtsxfpv | Tcqbkb | $28.4 Bil | |||
| Icon PLC
ICLR
| Tqmhyhk | Xphygc | $26.6 Bil | |||
| Illumina Inc
ILMN
| Hfvszkwp | Vvzkxr | $17.2 Bil | |||
| Labcorp Holdings Inc
LH
| Cwvntlgq | Cdzrmfq | $17.1 Bil | |||
| Waters Corp
WAT
| Cymvldvy | Hmsnb | $16.9 Bil |